Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 8/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18005387 | 0.97 | ALDH1A1 (0.45) | ALDH1A1HTTPDGFRBPDGFRAKDM4E | |
| SCHEMBL19890923 | 0.82 | PDGFRB (0.43) | ALDH1A1PDGFRBPDGFRAKDM4EGRM5 | |
| SCHEMBL3406476 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HTTKDM4ENPC1RAB9A | |
| SCHEMBL22176507 | 0.79 | FFAR4 (0.41) | ALDH1A1PDGFRBPDGFRAKDM4EGRM5 | |
| SCHEMBL19899744 | 0.79 | FFAR4 (0.41) | PDGFRBPDGFRAGRM5FFAR4LOX | |
| SCHEMBL18005388 | 0.77 | TLR9 (0.40) | PDGFRBPDGFRAGRM5FFAR4LOX | |
| SCHEMBL31403669 | 0.76 | NUDT1 (0.46) | PDGFRBPDGFRANPC1RAB9AGRM5 | |
| SCHEMBL3410707 | 0.76 | CDK4 (0.40) | PDGFRBPDGFRAGRM5FFAR4LRRK2 | |
| SCHEMBL26478038 | 0.74 | PDGFRB (0.41) | PDGFRBPDGFRAGRM5FFAR4LOX | |
| SCHEMBL19510867 | 0.74 | FFAR4 (0.39) | ALDH1A1PDGFRBPDGFRAGRM5FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2016133959-A9 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2016133959-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133959-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| CN-101952275-B | Modulators for amyloid protein beta | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | SDHA, CYP11B1, CYP11B2 | ALDH1A1 176/4885HTT 1850/4885PDGFRB 2373/4885 |
| US-10364227-B2 | Therapeutic compounds | SDHA, CYP11B1, CYP11B2 | ALDH1A1 176/4885HTT 1850/4885PDGFRB 2373/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | ALDH1A1 2956/4885HTT 22/4885PDGFRB 992/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | ALDH1A1 2860/4885HTT 19/4885PDGFRB 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.